20-F: Gelteq 2025: Product Development & Financial Challenges

Gelteq Limited's 2025 annual report highlights significant product development and strategic partnerships amidst recurring operating losses and going concern doubts.

Summary

• Gelteq specializes in gel-based oral drug delivery systems, focusing on white-label solutions for prescription drugs, nutraceuticals, pet care, and other products.
• The company reported a loss after income tax of AUD$6,645,453 for the fiscal year ended June 30, 2025, an increase from AUD$3,546,195 in 2024.
• Revenue from contracts with customers increased to AUD$165,645 in FY2025 from nil in FY2024, primarily from delayed orders that were fulfilled.
• Research expenses increased by 56% to AUD$628,606 in FY2025, driven by product testing, validations, and setting up new laboratory facilities.
• Corporate and administrative expenses rose significantly by AUD$3,228,547 to AUD$6,470,488 in FY2025, mainly due to IPO-related costs, professional fees, and finance costs.
• Gelteq entered into a Product Development and Profit Share Agreement with Melbourne Health (The Royal Melbourne Hospital) on July 31, 2025, to develop products incorporating HAMSB for bowel cancer risk reduction.
• The company secured an Equity Financing Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC for up to $12,000,000 in Ordinary Shares, with the registration statement declared effective on August 29, 2025.
• Gelteq received FDA approval for a suitability petition for a new animal drug under development in December 2024, leveraging its gel platform.
• The company continues to expand its intellectual property portfolio with new patent applications for oil-based products, dysphagia market products, and single Active Pharmaceutical Ingredient (API) formulations.
• As of June 30, 2025, there is a deficit of current assets over current liabilities of AUD$4,125,457, raising substantial doubt about the company's ability to continue as a going concern.
• Management forecasts revenue to increase at an average rate of approximately 213% annually over the next four years from FY2025, targeting veterinary, healthcare, and nutraceutical markets.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses and a 'going concern' doubt, which are major negatives. However, strategic progress in product development, intellectual property expansion, and securing capital through an IPO and ELOC provide some positive momentum and future potential, preventing a lower score.

Positives

• Secured a Product Development and Profit Share Agreement with Melbourne Health for a product with potential to reduce bowel polyp growth.
• Received FDA approval for a suitability petition for a new animal drug, potentially accelerating the approval pathway by foregoing safety and effectiveness studies.
• Successfully completed an initial public offering (IPO) on October 30, 2024, raising USD$5.2 million in gross proceeds.
• Established an Equity Financing Line of Credit (ELOC) with Lincoln Park Capital Fund, LLC for up to $12,000,000, providing access to additional capital.
• Increased revenue from contracts with customers to AUD$165,645 in FY2025, fulfilling previously delayed orders.
• Expanded intellectual property portfolio with new provisional patent applications for various gel delivery challenges and pharmaceutical formulations.
• Maintained a research partnership with Monash University, a top-ranked institution in pharmaceutical science.
• Forecasts significant revenue growth at an average rate of 213% annually over the next four years, targeting large and growing markets.

Negatives

• Incurred substantial operating losses of AUD$6,645,453 in FY2025, an increase from AUD$3,546,195 in FY2024.
• Audited financial statements include an explanatory paragraph on substantial doubt about the company's ability to continue as a going concern.
• Current liabilities exceeded current assets by AUD$4,125,457 as of June 30, 2025.
• Operating expenses significantly increased in FY2025, driven by IPO-related costs, professional fees, and finance costs.
• Reliance on third parties for manufacturing, marketing, and distribution introduces risks to timely and cost-effective product delivery and revenue generation.
• Customers have a history of delaying orders due to cash flow difficulties, impacting timely revenue generation.
• The company is not compliant with Nasdaq Rule 5605(c)(2) requiring an audit committee of at least three independent directors due to recent resignations.
• Significant portion of total assets (92.47% in FY2025) are intangible assets, whose recoverability relies on aggressive revenue growth forecasts.

Risks

• History of operating losses and uncertainty of achieving or sustaining profitability in the future.
• Requirement for substantial additional financing, with failure to obtain it potentially forcing delays or termination of product development/commercialization.
• Operating results may fluctuate due to the new class of products and unknown demand, making results difficult to predict.
• Fluctuations in raw material prices can increase product costs and impact production commitments.
• Customers have a history of delaying orders, adversely affecting revenues and income.
• Substantial doubt about the company's ability to continue as a going concern.
• Global geopolitical conditions (Russia-Ukraine, Middle East conflicts, U.S. tariffs) may adversely affect business and capital raising ability.
• Market for gels may not develop, expand slowly, or become saturated, impacting revenues.
• Success depends on obtaining market acceptance for products and services.
• Loss of key personnel, particularly CEO Nathan J. Givoni, would negatively affect the business.
• Significant resources spent on research may not lead to successful products or recovery of expenditures, or regulatory approval.
• Reliance on third parties for manufacturing and distribution could adversely impact revenues and profit margins.
• Reliance on a limited number of suppliers for raw materials poses risks to meeting customer orders.
• Inability to adequately control costs associated with operations.
• Failure to keep up with rapid technological change could materially and adversely affect financial condition.
• Legal requirements and changes in applicable law and regulations may adversely affect the company, especially if products are reclassified as drugs.
• Potential product liability claims could result in substantial liability and costs.
• Changes in tax rates, new tax legislation, or exposure to additional tax liabilities.
• Fluctuations in exchange rates could adversely affect results of operations.
• Acquisitions, joint ventures, investments, and divestitures could result in operating difficulties, dilution, and other consequences.
• Risks related to doing business in the PRC, including economic/political conditions, legal interpretation uncertainties, and trade tensions.
• Inability to prevent unauthorized use of intellectual property, particularly in the PRC.
• Intellectual property disputes could lead to significant liability and divert management attention.
• Information technology system failures or network security breaches could interrupt operations.
• Failure to comply with privacy policies or legal/regulatory requirements could result in penalties.
• Evolving definitions of Personal Information/Data may limit business expansion.
• Failure to comply with anticorruption and anti-money laundering laws.
• Adverse impact from failure to comply with U.S. and international import and export laws.
• Potential write-down of substantial intangible assets due to impairment.
• Costs and obligations of being a U.S. public company.
• Future or current litigation could have a material adverse impact.
• Australian tax rules may adversely impact financial results.
• Management and board control a significant percentage of Ordinary Shares, potentially influencing shareholder matters.
• Shareholders may have greater difficulty enforcing interests due to Australian incorporation.
• U.S. shareholders may have difficulty enforcing civil liabilities against the company or its non-U.S. directors/management.
• Australian takeover laws may discourage takeover offers.
• Constitution and Australian laws may adversely affect ability to take beneficial actions for shareholders.
• Reporting under IFRS differs from U.S. GAAP, potentially affecting comparability.
• Exemption from certain U.S. securities laws as a foreign private issuer may afford less protection to shareholders.
• Potential loss of foreign private issuer status could result in significant additional cost.
• Reduced disclosure requirements as an emerging growth company could make Ordinary Shares less attractive.
• Failure to develop or maintain effective disclosure controls and internal control over financial reporting.
• Potential classification as a passive foreign investment company (PFIC) could have adverse U.S. federal income tax consequences.
• If a U.S. person owns at least 10% of Ordinary Shares, they may be subject to adverse U.S. federal income tax consequences.
• Failure to meet Nasdaq continued listing requirements could result in delisting.
• Extreme volatility in stock price due to small public float.
• Unlikely to issue dividends for the foreseeable future.
• Dividend payments in U.S. Dollars subject shareholders to exchange rate fluctuations.

Future Outlook

Gelteq plans to prioritize pharmaceutical research, specifically pursuing the 505(b)(2) pathway for its own gel-based prescription drug, and undertaking numerous clinical trials to demonstrate its gel-based platform's performance across various drug classes. The company is in discussions with potential partners for nutraceutical white-labeled products and expects to grow revenue at an average rate of 213% annually over the next four years, targeting veterinary, healthcare, and nutraceutical markets. New hires, particularly three additional sales managers, are planned for FY2026 to assist in meeting revenue targets. Formal studies for canine products are expected to begin in FY2026.

Management Comments

• We have prioritized pharmaceutical research and improving operational processes, and we expect to grow and execute on our business plans with lower overheads and expenses in the financial year ending June 30, 2026.
• We are prioritizing our sales activities with a focus on the animal health, nutraceutical, sports, over-the-counter and pharmaceuticals verticals for the year ending June 30, 2026.
• We remain confident in our sales strategy and our strong existing new business pipeline, and we would fulfil our revenue numbers should each existing potential client in the pipeline eventuate.
• We believe that the initial sales may generate the conditions for further revenues which would improve our financial position.
• We have been focused on selecting the right new hires to directly assist us to reach our revenue targets, with these hires to be spread across the business to ensure all sectors are adequately staffed and working towards business performance.

Industry Context

Gelteq operates in the rapidly evolving oral drug delivery market, which is estimated at USD$134 billion in 2025 and projected to grow to USD$170 billion by 2030. The company aims to innovate in this space, which has seen modest innovation since the 19th century. Its focus on pet health aligns with the growing 'pet humanization' trend, driving increased consumer spending on pet health products and supplements (e.g., 53% of dog owners and 34% of cat owners provided supplements in 2025). The nutraceuticals market is also expanding, expected to grow from USD$140 billion in 2020 to USD$270 billion by 2028, driven by consumer demand for health benefits. Gelteq's gel delivery system addresses unmet needs in dysphagia (difficulty swallowing) and taste masking, offering a differentiated solution in these markets. The company also targets the sports nutrition market, where athletes seek efficient delivery of ergogenic aids.

Comparison to Industry Standards

• Monash University, Gelteq's academic partner, is ranked among the top universities globally in pharmaceutical science by the 2024 QS World University Rankings for Pharmacy & Pharmacology, indicating a strong research foundation.
• Gelteq's forecast revenue in each target market (veterinary medications, healthcare/oral drug delivery, nutraceuticals/sports) remains less than 0.05% of the total addressable sales, suggesting significant headroom for growth compared to market size benchmarks.
• The forecast model's long-term EBITDA margin of 35% (by FY30) is projected to be comparable to that of comparable industries in relevant world markets, indicating an ambition to achieve industry-standard profitability as the business matures.
• The company's approach to the 505(b)(2) pathway for drug approval is a recognized strategy for faster market entry compared to full New Drug Applications (NDAs), which is a common industry practice for reformulations of approved APIs.

Management Changes

Corporate Governance

Legal Proceedings

• No material litigation or regulatory matters are currently known to be threatened or pending against the company that would have a material and adverse effect on its business.

Related Party Transactions

• Shareholder Loan Agreements: Loans from B&M Givoni Pty Ltd ATF B&M Givoni Superannuation Fund (related to CEO Nathan J. Givoni's parents) and former director Jeffrey W. Olyniec, with principal amounts of $350,000 and AUD$143,445 respectively, at 12% interest, extended to December 31, 2025.
• Provision of Services by Asiana Trading Corporation Limited: Paid AUD$546,564 in FY2025 (AUD$9,125 in FY2024) for management services in China. Former director Jeffrey W. Olyniec was the sole shareholder until December 2021 but received none of the amounts paid.
• Loans from associated entities: Unsecured loans from Nutrition DNA and Domalina Unit Trust (entities associated with Nathan Givoni) with a 0.5% interest rate, extended to December 31, 2026.
• Convertible Notes from Related Parties: Convertible notes issued to entities related to Nathan Givoni and Jeffrey Olyniec (for 2024) and Nathan Givoni (for 2025), with various interest rates and maturity dates, some converted into shares or repaid.

Stakeholder Impact

• Shareholders: Face significant risk due to recurring operating losses, substantial doubt about going concern, and potential dilution from future capital raises. However, strategic progress and new agreements offer long-term growth potential.
• Employees: The company plans to increase staffing, particularly in sales, which could lead to new employment opportunities. Compensation for key management personnel is detailed.
• Customers: Delayed orders due to customer cash flow issues have been resolved, and new rigorous qualification procedures are in place. The focus on white-label solutions and partnerships aims to serve a wider customer base.
• Suppliers: Reliance on a limited number of raw material suppliers and third-party manufacturers creates supply chain risks, potentially affecting the company's ability to meet customer orders.
• Creditors: The company has extended maturity dates for shareholder loans and convertible notes to alleviate short-term liabilities, but the going concern doubt poses a risk to timely debt repayment.

Next Steps

• Pursue the 505(b)(2) pathway for its own gel-based prescription drug.
• Undertake numerous clinical trials to demonstrate the gel-based platform's performance across various drug classes.
• Engage in discussions with potential companies for development and distribution of nutraceutical white-labeled products.
• Onboard an additional three sales managers in FY2026 to assist in meeting revenue targets.
• Begin formal studies for canine products in the fiscal year ending June 30, 2026.
• Appoint two additional independent directors to the board and Audit Committee in early 2026 to regain Nasdaq compliance.

Key Dates

Recommendation

Gelteq Limited presents a high-risk, high-reward investment profile. The company's recurring operating losses and the 'going concern' qualification from its auditor are significant red flags, indicating substantial financial instability and a need for ongoing capital. However, the strategic progress, including the Product Development and Profit Share Agreement with Melbourne Health, the FDA suitability petition approval for an animal drug, and the secured ELOC for up to $12 million, demonstrate a clear path for product commercialization and capital access. The company's focus on expanding its intellectual property and targeting large, growing markets (pet health, nutraceuticals, oral drug delivery) with a unique gel-based technology offers considerable long-term potential. Given the inherent risks but also the strategic advancements and recent capital-raising efforts, a 'hold' recommendation is appropriate for investors who are comfortable with high risk and believe in the long-term potential of the company's innovative technology, while closely monitoring its financial performance and execution of its strategic plans.

Keywords

Gelteq, gel-based delivery, pharmaceuticals, nutraceuticals, pet care, oral drug delivery, HAMSB, Royal Melbourne Hospital, SEC filing, 20-F, biotechnology, drug development, IPO, Nasdaq, Lincoln Park Capital, ELOC, FDA approval, animal health, dysphagia, intellectual property, operating losses, going concern, Australia